secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008129
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q1 net loss $0.22/shr; cash $12.7M; GT-02287 Phase 1 SAD positive
--------------------------------------------------------------------------------

- GAAP net loss per share $0.22 (Q1 2024) vs $0.43 (Q1 2023); narrower loss.
- Cash, equivalents & marketable securities $12.7M as of March 31, 2024; cash runway guided into 2025.
- R&D expenses $2.5M (down from $2.8M YoY); G&A expenses $1.9M (down from $2.5M YoY).
- Positive SAD data for GT-02287; MAD part of Phase 1 initiated for GBA1 Parkinson’s disease.
- Appointed Gene Mack as CFO and Jonas Hannestad, M.D., Ph.D. as CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/0001558370-24-008129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837024008129/ganx-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer